Merck’s Winrevair reduced clinical worsening in PAH patients in the Phase 3 HYPERION trial, building on prior positive study outcomes.
Merck’s Hypertension Drug Cuts Clinical Worsening Risk In Over 70% Of Patients On Double Background Therapy
Where Today's News Shapes Tomorrow
